Drug Trial Radar · NCT07201129
A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment
Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
300
Planned (sponsor's estimate)
Start
Feb 9, 2026
Primary completion
Aug 2029
Study completion Feb 2030
Sponsor
- Lead sponsor
- Viatris Innovation GmbHIndustry
- Sponsor type
- Industry
- First posted
- Oct 1, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if cenerimod, on top of regular treatment, works to treat active lupus nephritis in adults with systemic lupus erythematosus and active lupus nephritis. It will also learn about the safety of cenerimod. The main questions it aims to answer are: * Does cenerimod improve kidney function in participants? * What medical problems do participants have when taking cenerimod? Researchers will compare cenerimod to a placebo (a look-alike substance that contains no drug) to see how well cenerimod works when it is added to regular treatment. Participants will: * Take cenerimod or a placebo every day for 76 weeks (approximately 1.5 years), on top of regular treatment. * Visit the clinic every 1 to 3 months for checkups and tests.
Conditions
- Nephritis, Lupus
- Lupus Erythematosus, Systemic
Interventions
CenerimodDrug
Cenerimod will be supplied as a film-coated tablets at the dose of 4 mg.
PlaceboDrug
Matching placebo will be supplied as identical film-coated tablets formulated with the same excipients but without the active ingredient, cenerimod.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Complete renal response (CRR)Time frame: At Week 76
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
Dolphin Medical Research
Doral, Florida · Recruiting
Alloy Clinical Research LLC
Kissimmee, Florida · Recruiting
SouthCoast Research Center
Miami, Florida · Recruiting
Allied Biomedical Research Institute
Miami, Florida · Recruiting
DH NationalResearchCenters INC
Miami, Florida · Recruiting
ProfessionalResearchCenter INC
Miami, Florida · Recruiting
San Marcus Research Clinic, Inc.
Miami Lakes, Florida · Recruiting
Revive Research Institute, LLC
Sterling Heights, Michigan · Recruiting
Rheumatology Care Center, PLLC
Bellaire, Texas · Recruiting
Texas Arthritis Center
El Paso, Texas · Recruiting
Novel Research, LLC.
Houston, Texas · Recruiting
Northwest Houston Arthritis
Houston, Texas · Recruiting
Discovery Clinical Trials LLC
San Antonio, Texas · Recruiting
Azul Bioresearch Llc
Sugarland, Texas · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.